戻る Agenda
Community Discussion of Data Science in Relation to Drug Development
Session Chair(s)
Ruthie Davi, PHD, MS
Vice President, Data Science and Statistician
Medidata, a Dassault Systèmes Company, United States
Stella C. Grosser, PHD, MS
Division Director, Office of Biostatistics, OTS, CDER
FDA, United States
This will be a community discussion of data science. Several panelists with experience in the area will be available to share their knowledge.
Learning Objective : At the conclusion of this session, participants should be able to:
- Identify common issues in the overlap between data science, statistics, and drug development
- Describe examples where data science has impacted pharmaceuticals
- Identify techniques of data science to possibly improve the efficiency of drug development
Speaker(s)
Speaker
Nareen Katta, MBA, MS
AbbVie, United States
Head of Data Science & Analytics
Panelist
Paul Schuette, PHD, MA
FDA, United States
Mathematical Statistician, Scientific Computing Coordinator
Speaker
Matthew Austin, MS
Amgen, United States
Executive Director, Data Science
Panelist
Joan Buenconsejo, PHD, MPH
Bristol Myers Squibb, United States
Head of Cardiovascular and Neuroscience Biostatistics